AOTMiT: The Transparency Council will evaluate e.g. drugs for plasmacytoma, rheumatoid arthritis and renal anemia

The agenda includes:
Preparation of positions on the assessment of the legitimacy of qualifying healthcare services as guaranteed services:
• Percutaneous thermoablation using radiofrequency current (RFA) or microwaves (MWA) under the guidance of computed tomography in the indication of primary malignant tumors of the lung (ICD-10: C34.0, C34.1, C34.2, C34.3, C34. 8, C34.9), secondary malignant tumors of the lung (ICD-10: C78.0);
• Percutaneous radiofrequency (RFA) or microwave (MWA) thermal ablation guided by CT or MRI for secondary malignant bone tumors (ICD-10: C79.5), callous osteoma (ICD-10: D16.1) , D16.2, D16.3, D16.4, D16.5, D16.6, D16.7, D16.8, D16.9), primary malignant bone tumors (ICD-10: C40, C41);
• Percutaneous radiofrequency (RFA) or microwave (MWA) thermal ablation guided by computed tomography or magnetic resonance imaging or X-ray fluoroscopy with cementoplasty in the indication of secondary malignant bone tumors (ICD-10: C79.5), osteoma osteoma (ICD- 10: D16.1, D16.2, D16.3, D16.4, D16.5, D16.6, D16.7, D16.8, D16.9), primary malignant tumors of bone (ICD-10: C40, C41);
• Percutaneous thermoablation using radiofrequency current (RFA) or microwaves (MWA) under the control of computed tomography in the indication of adrenal tumors (ICD-10: C74, C79.7, D35.0);
• Percutaneous cryoablation guided by computed tomography or magnetic resonance imaging in the indication of secondary malignant bone tumors (ICD-10: C79.5);
• Percutaneous cryoablation guided by computed tomography or magnetic resonance imaging with cementoplasty in the indication of secondary malignant bone tumors (ICD-10: C79.5);
• Percutaneous cryoablation under computed tomography in the indication of malignant tumors of the chest (ICD-10: C34, C38, C78.0, C78.1, C78.2).
Preparation of positions on drug evaluation:
• Sarclis (isatuximab) as part of the drug program "Treatment of patients with multiple myeloma (ICD-10: C90.0)" in combination with pomalidomide and dexamethasone,
• Jyseleca (filgotinib) under the B.33 drug program. "Treatment of patients with active rheumatoid arthritis and juvenile idiopathic arthritis (ICD-10: M05, M06, M08)",
• Evrenzo (roxadustatum) under the drug program B.37. "Treatment of anemia in chronic renal failure (ICD-10 N 18)".
Preparation of a position on the legitimacy of granting consent for the reimbursement of the medicinal product Reducto spezial (potassium dihydrogen phosphate, sodium monohydrogen phosphate dihydrate) in the indication: hypophosphatemic rickets.
Preparation of opinions on draft health policy programs of local government units:
• "Health policy program of the Kleszczów Commune for the years 2023-2025 in the field of prevention of diseases of the teeth and oral cavity",
• "Health policy program for compulsory and recommended vaccinations with the use of a 6-in-1 highly combined vaccine" (Kleszczów commune),
• "The Słupsk program for counteracting the effects of infertility by co-financing treatment by in vitro fertilization for the years 2023-2027".
Preparation of an opinion on the reimbursement of drugs containing the active substance anakinra in the following indications: other congenital autoinflammatory syndromes: TRAPS, FMF after treatment failure with the maximum tolerated dose of colchicine; polygenic autoinflammatory syndromes mediated by IL1: – Schnitzler's syndrome; secondary amyloidosis, dependent on autoinflammatory changes.

Source: AOTMIT